Plain-English translation of NCT06374667 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called Y-3 that protects brain cells after a large stroke. The study compares two ways of delivering this medication: through a special injection into the skull bone (which may bypass the blood-brain barrier more effectively) versus a traditional intravenous injection into the arm. The goal is to see which method works better at protecting brain tissue and improving recovery.
Large strokes have a very high death rate and cause severe disability, and current treatments have significant limitations. Regular intravenous medications struggle to reach the brain because of the blood-brain barrier. This trial explores whether delivering the medication directly through the skull bone to reach the brain tissue more efficiently could save more lives and reduce brain damage.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to receive either the new injection method or the traditional intravenous injection of the medication. You will receive your assigned treatment once daily for 3 consecutive days, along with all standard stroke care. The trial involves hospital stays, imaging scans, and follow-up visits to monitor your recovery and safety over time.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
China